Improving Power in Randomized Controlled Trials with Time-to-Event Endpoints: A Risk-Free Approach

📅 2026-05-26
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
This study addresses the challenge of safely incorporating external high-dimensional prognostic information to enhance the statistical power of randomized controlled trials with time-to-event endpoints, without introducing bias or inflating Type I error. The authors propose a two-stage framework: first constructing a prognostic score using martingale residuals and supervised learning, then integrating this score as a covariate in a nonparametric covariate-adjusted log-rank test and marginal hazard ratio estimation. This approach enables robust utilization of external prognostic data, ensuring unbiased estimation of the marginal hazard ratio and valid Type I error control even under prognostic model misspecification or population heterogeneity. Theoretical analysis shows that the variance reduction is approximately equal to the squared correlation between the prognostic score and the martingale pseudo-outcome, and simulations confirm substantial gains in efficiency—reducing required event counts and increasing power when informative prognostic signals are present.
📝 Abstract
Leveraging external or historical data to improve the efficiency of randomized clinical trials without introducing bias or inflating the Type I error rate remains challenging. Recent work on externally trained prognostic scores, such as PROCOVA for continuous endpoint, has demonstrated a risk-free approach via covariate adjustment. However, extending this paradigm to time-to-event endpoints is nontrivial due to the non-collapsibility of the marginal hazard ratio (HR). In this paper, we address this challenge by proposing a unified framework for incorporating complex, high-dimensional prognostic information learned from external data into the primary analysis of RCTs with time- to-event endpoints, while targeting the marginal hazard ratio. The proposed procedure proceeds in two steps. First, a prognostic score is estimated from external or historical data by regressing martingale residuals on baseline covariates using flexible supervised learning methods. Second, the fitted score is included as an additional covariate in the nonparametric covariate-adjusted log-rank test and the associated marginal HR estimator of Ye et al. [2024]. The proposed method controls Type I error and provides asymptotic unbiased estimation of the marginal HR, irrespective of prognostic model misspecification, or population heterogeneity between external/historical and trial data. We show that the variance reduction, and corresponding event count savings, are approximately equal to the squared correlation between the prognostic score and the martingale pseudo-outcome in the trial. Extensions to stratified randomization are straightforward. Simulation studies demonstrate satisfactory finite-sample performance and meaningful efficiency gains when historical prognostic information is informative.
Problem

Research questions and friction points this paper is trying to address.

randomized controlled trials
time-to-event endpoints
prognostic scores
marginal hazard ratio
external data
Innovation

Methods, ideas, or system contributions that make the work stand out.

prognostic score
time-to-event endpoint
marginal hazard ratio
covariate adjustment
external data
💼 Related Jobs
No related jobs found.
J
Junyi Zhou
Amgen Inc.
Q
Qing Liu
Amgen Inc.
M
May Mo
Amgen Inc.
A
Amy Xia
Amgen Inc.